The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest?
Dalhousie University, Department of Medicine, QE II Health Sciences Centre, Halifax, NS, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(2), 77-79; https://doi.org/10.3747/co.22.2579
Submission received: 2 January 2015
/
Revised: 12 February 2015
/
Accepted: 9 March 2015
/
Published: 1 April 2015
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]
Share and Cite
MDPI and ACS Style
Younis, T.; Groom, A. The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest? Curr. Oncol. 2015, 22, 77-79. https://doi.org/10.3747/co.22.2579
AMA Style
Younis T, Groom A. The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest? Current Oncology. 2015; 22(2):77-79. https://doi.org/10.3747/co.22.2579
Chicago/Turabian StyleYounis, T., and A. Groom. 2015. "The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest?" Current Oncology 22, no. 2: 77-79. https://doi.org/10.3747/co.22.2579
